Seeking Alpha

Despite reporting a weak Q4 and lowering Q1 2012 guidance, AngioDynamics (ANGO +10%) trades...

Despite reporting a weak Q4 and lowering Q1 2012 guidance, AngioDynamics (ANGO +10%) trades higher after Canaccord upgrades the stock to buy on valuation. The firm says the company's NanoKnife sales for the recent quarter were impressive, and the product has significant upside potential.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|